{"id":"F2017L01259","name":"National Health (Pharmaceutical Benefits Scheme- class of pharmaceutical items – Subsection 99ACA(3) Determination 2017","slug":"national-health-pharmaceutical-benefits-scheme-class-of-pharmaceutical-items-subsection-99aca-3-dete","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":97178,"registerId":"commonwealth-F2017L01259-current","compilationNumber":null,"startDate":"2026-04-02","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"National Health (Pharmaceutical Benefits Scheme- class of pharmaceutical items – Subsection 99ACA(3) Determination 2017","content":"![](image.001.png)\n\nPB 82 of 2017\n\nNational Health (Pharmaceutical Benefits Scheme\\- class of pharmaceutical items - Subsection 99ACA(3)) Determination 2017\n\nNational Health Act 1953\n\nI, LISA LA RANCE, Assistant Secretary, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ACA(3) of the National Health Act 1953.\n\nDated 19 September 2017\n\nLISA LA RANCE\n\nAssistant Secretary\n\nPricing and Policy Branch\n\nTechnology Assessment and Access Division\n\nDepartment of Health\n\n1 Name of Instrument\n\n(1) This instrument is the National Health (Pharmaceutical Benefits Scheme\\- class of pharmaceutical items – Subsection 99ACA(3) Determination 2017.\n\n(2) This instrument may also be cited as PB 82 of 2017.\n\n2 Commencement\n\nThis instrument commences on the date of registration on the Federal Register of Legislation.\n\n3 Revocation\n\nThe Determination under subsection 99ACA(3) of the National Health Act 1953 (PB 59 of 2007) is revoked.\n\n4 Authority\n\nThis Determination is made under subsection 99ACA (3) of the National Health Act 1953.\n\n5 Definitions\n\nIn this Determination:\n\nAdministrative price reduction means a non-statutory price reduction that has been agreed under section 85AD of the Act.\n\nNote: Terms used in this Determination have the same meaning as in the Act – see section 13 of the Legislation Act 2003. These terms include:\n\n-   pharmaceutical item\n-   listed component drug\n-   manner of administration\n\n6 Class of pharmaceutical items\n\nThe class of pharmaceutical items identified in the Schedule, by listed component drug and manner of administration, have taken a 12.5% administrative price reduction.\n\n  \n\nSchedule\n\n| LISTED COMPONENT DRUG            | MANNER OF ADMINISTRATION |\n| -------------------------------- | ------------------------ |\n| Aciclovir                        | Oral                     |\n| Amitriptyline                    | Oral                     |\n| Amoxycillin                      | Oral                     |\n| Amoxycillin with Clavulanic Acid | Oral                     |\n| Bisacodyl                        | Oral                     |\n| Bupropion                        | Oral                     |\n| Calcitriol                       | Oral                     |\n| Calcium Folinate                 | Injection                |\n| Captopril                        | Oral                     |\n| Carboplatin                      | Injection                |\n| Cefaclor                         | Oral                     |\n| Cefotaxime                       | Injection                |\n| Ceftriaxone                      | Injection                |\n| Cefuroxime                       | Oral                     |\n| Cephalexin                       | Oral                     |\n| Cimetidine                       | Oral                     |\n| Ciprofloxacin                    | Oral                     |\n| Cisplatin                        | Injection                |\n| Citalopram                       | Oral                     |\n| Clarithromycin                   | Oral                     |\n| Codeine with Paracetamol         | Oral                     |\n| Cromoglycic Acid                 | Application to the eye   |\n| Dexamphetamine                   | Oral                     |\n| Docetaxel                        | Injection                |\n| Dolasetron                       | Injection                |\n| Dolasetron                       | Oral                     |\n| Doxorubicin                      | Injection/Intravesical   |\n| Electrolyte Replacement (Oral)   | Oral                     |\n| Enalapril                        | Oral                     |\n| Erythromycin                     | Oral                     |\n| Escitalopram                     | Oral                     |\n| Esomeprazole                     | Oral                     |\n| Etidronic Acid and Calcium       | Oral                     |\n| Etoposide                        | Injection                |\n| Famciclovir                      | Oral                     |\n| Famotidine                       | Oral                     |\n| Fluconazole                      | Oral                     |\n| Fluorouracil                     | Injection                |\n| Fluoxetine                       | Oral                     |\n| Fluvastatin                      | Oral                     |\n| Fluvoxamine                      | Oral                     |\n| Fosinopril                       | Oral                     |\n| Frusemide                        | Injection                |\n| Gabapentin                       | Oral                     |\n| Gliclazide                       | Oral                     |\n| Glimepiride                      | Oral                     |\n| Granisetron                      | Oral                     |\n| Granisetron                      | Injection                |\n| Imipramine                       | Oral                     |\n| Ipratropium                      | Inhalation               |\n| Irinotecan                       | Injection                |\n| Lansoprazole                     | Oral                     |\n| Lamotrigine                      | Oral                     |\n| Levetiracetam                    | Oral                     |\n| Lisinopril                       | Oral                     |\n| Metformin                        | Oral                     |\n| Methotrexate                     | Injection                |\n| Methylphenidate                  | Oral                     |\n| Mirtazapine                      | Oral                     |\n| Mitozantrone                     | Injection                |\n| Moclobemide                      | Oral                     |\n| Naratriptan                      | Oral                     |\n| Nizatidine                       | Oral                     |\n| Omeprazole                       | Oral                     |\n| Ondansetron                      | Injection                |\n| Ondansetron                      | Oral                     |\n| Oxaliplatin                      | Injection                |\n| Oxcarbazepine                    | Oral                     |\n| Paclitaxel                       | Injection                |\n| Pantoprazole                     | Oral                     |\n| Paracetamol                      | Oral                     |\n| Paroxetine                       | Oral                     |\n| Pemetrexed                       | Injection                |\n| Perindopril                      | Oral                     |\n| Pravastatin                      | Oral                     |\n| Quinapril                        | Oral                     |\n| Rabeprazole                      | Oral                     |\n| Ramipril                         | Oral                     |\n| Ranitidine                       | Oral                     |\n| Reboxetine                       | Oral                     |\n| Roxithromycin                    | Oral                     |\n| Sertraline                       | Oral                     |\n| Simvastatin                      | Oral                     |\n| Sumatriptan                      | Oral                     |\n| Terbinafine                      | Oral                     |\n| Tiagabine                        | Oral                     |\n| Topiramate                       | Oral                     |\n| Tramadol                         | Injection                |\n| Tramadol                         | Oral                     |\n| Trandolapril                     | Oral                     |\n| Tropisetron                      | Injection                |\n| Tropisetron                      | Oral                     |\n| Valaciclovir                     | Oral                     |\n| Vigabatrin                       | Oral                     |\n| Vinorelbine                      | Injection                |\n| Zolmitriptan                     | Oral                     |","sortOrder":0}],"analysis":{"flash_summary":{"complexity_score":3,"scope_assessment":{"changed":true,"description":"This instrument expressly revokes the earlier Determination (PB 59 of 2007) and replaces it with a new Schedule applying a 12.5% administrative price reduction to listed PBS items (cl.3, cl.6, Schedule). The text changes the operative instrument and the defined class; comparison to the prior list is required to determine the exact substantive differences but that prior list is not included here."},"complexity_factors":["Fixed-percentage adjustment (12.5%) applied uniformly to a class reduces legal complexity but increases operational work for affected parties (cl.6; Schedule).","Large, itemised Schedule with many drugs and multiple manners of administration creates administrative mapping and implementation tasks for payers and suppliers (Schedule).","Revocation of a prior instrument requires stakeholders to reconcile old and new lists and systems (cl.3).","Determination is made by a departmental delegate under statutory power, so legal basis is straightforward but depends on cross-references to the National Health Act (cl.4).","Definition reliance: terms (eg. 'pharmaceutical item', 'listed component drug', 'manner of administration') are borrowed from the Act and Legislation Act, requiring cross-reference when applying the Schedule (cl.5).","Interplay with non‑statutory 'administrative price reduction' and section 85AD of the Act may create commercial negotiation and accounting effects outside this Determination (cl.5 Note).","Low legislative drafting complexity — the instrument is short and prescriptive — but operational/compliance complexity rises from updating pricing systems and supplier contracts (cl.1–6, Schedule)."],"plain_english_summary":"This Determination imposes a 12.5% administrative price reduction on a defined class of Pharmaceutical Benefits Scheme (PBS) items, specified by listed component drug and manner of administration in the Schedule. It revokes the prior subsection 99ACA(3) Determination and takes effect on registration.\n\nThe change alters the administrative price used for PBS reimbursement, directly affecting suppliers/manufacturers, PBS payers and dispensers; it is made by a Department of Health delegate under subsection 99ACA(3) of the National Health Act 1953."},"kimi_summary":{"content_quality":"ok","complexity_score":2,"scope_assessment":{"changed":false,"description":"This determination performs exactly the function intended by subsection 99ACA(3) of the National Health Act 1953: identifying specific pharmaceutical items that have taken an administrative price reduction. The scope remains tightly focused on this single purpose."},"complexity_factors":["Very short instrument (6 sections plus schedule)","Only 1 defined term ('Administrative price reduction')","No cross-references to other legislation beyond the enabling Act","Simple tabular schedule with only 2 columns (drug name and administration method)","No conditional logic, exceptions, or nested provisions","Straightforward operative provision (section 6) with single outcome"],"plain_english_summary":"This determination imposes a 12.5% administrative price reduction on a defined list of 88 PBS medicines, cutting what the government pays for those products based on name and form. It directly affects suppliers to the PBS and reduces government expenditure, with downstream effects for taxpayers and patients. The change is a negotiated cost-control measure intended to help keep PBS spending sustainable without new legislation."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/national-health-pharmaceutical-benefits-scheme-class-of-pharmaceutical-items-subsection-99aca-3-dete","history":"/api/acts/national-health-pharmaceutical-benefits-scheme-class-of-pharmaceutical-items-subsection-99aca-3-dete/history","analysis":"/api/acts/national-health-pharmaceutical-benefits-scheme-class-of-pharmaceutical-items-subsection-99aca-3-dete/analysis","conflicts":"/api/acts/national-health-pharmaceutical-benefits-scheme-class-of-pharmaceutical-items-subsection-99aca-3-dete/conflicts","importantCases":"/api/acts/national-health-pharmaceutical-benefits-scheme-class-of-pharmaceutical-items-subsection-99aca-3-dete/important-cases","documents":"/api/acts/national-health-pharmaceutical-benefits-scheme-class-of-pharmaceutical-items-subsection-99aca-3-dete/documents"}}